In an unusual move, the Institute for Clinical and Economic Review has reversed course and decided a pair of new drugs for treating acute migraine attacks have greater value than thought initially. And the cost-effectiveness watchdog is pointing to its decision as an example of its willingness to exercise greater flexibility in the face of long-standing criticism of its approach to evaluating new medicines.

The nonprofit reassessed the drugs — Ubrelvy from Allergan (AGN) and another from Biohaven Pharmaceuticals (BHVN) that is not yet available — after reviewing a re-analysis of clinical trials it asked Allergan to conduct. ICER determined the Allergan tablet deserved a revised value closer to the $4,900 list price. Given both drugs are quite similar, ICER also determined the Biohaven drug should be priced the same.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy